Documents

A list of downloadable documents created during development.

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: equality impact assessment - guidance review

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: equality impact assessment form (post referral)

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: NICE response to consultee and commentator comments on the draft scope and provisional matrix (post-referral)

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: final matrix (post-referral)

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: final scope (post-referral)

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: draft scope for consultation (pre-referral) - August 2013

Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: provisional matrix (pre-referral) - August 2013